Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23536894 | 1.00 | HDAC4 (0.30) | HDAC4 | |
| SCHEMBL23536892 | 1.00 | HDAC4 (0.30) | HDAC4 | |
| SCHEMBL23547904 | 1.00 | HDAC4 (0.30) | HDAC4 | |
| SCHEMBL28863491 | 0.90 | HDAC4 (0.30) | HDAC4 | |
| SCHEMBL28863493 | 0.90 | HDAC4 (0.30) | HDAC4 | |
| Fluralaner SCHEMBL121934 | 0.89 | CA1 (0.32) | HDAC4 | |
| Fluralaner SCHEMBL29362559 | 0.89 | CA1 (0.32) | HDAC4 | |
| Fluralaner SCHEMBL8513367 | 0.89 | CA1 (0.32) | HDAC4 | |
| Fluralaner SCHEMBL8515337 | 0.89 | CA1 (0.32) | HDAC4 | |
| Fluralaner SCHEMBL29399660 | 0.89 | CA1 (0.32) | HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070879-A1 | ISOXAZOLINE DERIVATIVES | ELANCO TIERGESUNDHEIT AG (CH) | 2026-03-12 | — | — | US | disclosed |
| US-12497370-B2 | Isoxazoline derivatives | ELANCO TIERGESUNDHEIT AG (CH) | 2025-12-16 | — | — | US | disclosed |
| EP-4077286-A1 | ISOXAZOLINE DERIVATIVES AS PESTICIDES | Elanco Tiergesundheit AG (CH) | 2022-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12497370-B2 | Isoxazoline derivatives | CYP3A7, CYP4X1, CYP2A7 | HDAC4 779/4885 |
| US-20260070879-A1 | ISOXAZOLINE DERIVATIVES | CHRM1, CBR3, AFF1 | HDAC4 1167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.